Literature DB >> 21388265

Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents.

Roland F Staack1, Jan O Stracke, Kay Stubenrauch, Rudolf Vogel, Julia Schleypen, Apollon Papadimitriou.   

Abstract

Ligand-binding assays are the standard technology used for bioanalysis of therapeutic proteins, for example, for drug quantification (pharmacokinetics assays) and immunogenicity testing (antidrug antibody assays). Besides the selection of the most suitable technology platform (e.g., ELISA, electrochemiluminescence assays and surface plasmon resonance assays) and assay procedure, a pivotal prerequisite for good assay performance on any technology platform is the design, production and characterization of high quality reagents. To enable bioanalytical project support over the complete product life cycle, an appropriate long-term reagent supply is needed. This perspective describes our opinion on the requirements for generation and QC of critical reagents used in ligand-binding assays for drug quantification and antidrug antibody detection to enable high-quality assays and long-term supply, including reagent batch switches. The critical parameters during reagent design, production and long-term supply, along with the appropriate analytical methods for QC testing and appropriate certification, are discussed.

Mesh:

Substances:

Year:  2011        PMID: 21388265     DOI: 10.4155/bio.11.16

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  6 in total

Review 1.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

2.  Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics.

Authors:  Rand Jenkins; Jeffrey X Duggan; Anne-Françoise Aubry; Jianing Zeng; Jean W Lee; Laura Cojocaru; Dawn Dufield; Fabio Garofolo; Surinder Kaur; Gary A Schultz; Keyang Xu; Ziping Yang; John Yu; Yan J Zhang; Faye Vazvaei
Journal:  AAPS J       Date:  2014-11-13       Impact factor: 4.009

3.  Recommendations and best practices for reference standards and reagents used in bioanalytical method validation.

Authors:  Joseph F Bower; Jennifer B McClung; Carl Watson; Takahiko Osumi; Kátia Pastre
Journal:  AAPS J       Date:  2014-02-06       Impact factor: 4.009

4.  Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.

Authors:  Lindsay E King; Esme Farley; Mami Imazato; Jeannine Keefe; Masood Khan; Mark Ma; K Susanne Pihl; Priya Sriraman
Journal:  AAPS J       Date:  2014-04-01       Impact factor: 4.009

5.  Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays.

Authors:  Robert J Kubiak; Nancy Lee; Yuan Zhu; William R Franch; Sophia V Levitskaya; Surekha R Krishnan; Varghese Abraham; Peter F Akufongwe; Christopher J Larkin; Wendy I White
Journal:  J Immunol Res       Date:  2016-07-10       Impact factor: 4.818

6.  The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.

Authors:  Eugenia Opolka-Hoffmann; Gregor Jordan; Michael Otteneder; Robin Kieferle; Martin Lechmann; Gerhard Winter; Roland F Staack
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.